Last reviewed · How we verify
Malignant neoplasm of colon and/or rectum
Approved treatments
- Avastin · Washington University School of Medicine
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors. - Cyramza · Eli Lilly
Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant neoplasm of colon and/or rectum patent landscape — cliff calendar, originator estates, attackable patents
- Malignant neoplasm of colon and/or rectum treatment landscape brief
- Malignant neoplasm of colon and/or rectum treatment updates RSS
Frequently asked questions about Malignant neoplasm of colon and/or rectum
What drugs treat Malignant neoplasm of colon and/or rectum?
Tracked treatments include Avastin, Bevacizumab, Cyramza.
What is the treatment for Malignant neoplasm of colon and/or rectum?
Standard treatment for Malignant neoplasm of colon and/or rectum includes Avastin, Bevacizumab, Cyramza. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant neoplasm of colon and/or rectum patent cliff · Malignant neoplasm of colon and/or rectum CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- Treatment: Cyramza · Eli Lilly
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing